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Abstract  
 
 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare, although 
highly lethal, inherited arrhythmogenic disease. It constitutes an important health burden as 
may cause sudden cardiac death in young otherwise healthy subjects. Characteristically it 
manifests as exercise or emotion-induced syncopal events and a distinctive pattern of 
reproducible, stress- related, bi-directional ventricular tachycardia. 
 Clinical evaluation by exercise stress testing and holter monitoring can facilitate early 
identification, even though molecular genetic screening is critical to confirm uncertain 
diagnosis of CPVT. 
 An autossomal-dominant form (related to mutations in the gene that codifies the 
Ryanodine Receptor 2) and an autossomal- recessive form (related to mutations on the cardiac 
isoform of calsequestrin 2) have been well described, and a mutation on either of these genes 
is found in 50 to 70%  of  patients with this syndrome. 
 The basic arrhythmogenic mechanism of CPVT is thought to be deregulated leak of 
calcium from the sarcoplasmatic reticulum causing intracytoplasmatic overload and thus 
potentiating delayed afterdepolarizations and triggered activity. 
 It is generally accepted that ß-blocker agents are the cornerstone of chronic CPVT 
therapy, nonetheless, many patients still remain symptomatic; recurrence and mortality 
remain high and many patients require an implantable cardioverter defibrillator. A great 
number of innovative therapeutic options have been described and seem promising but more 
investigation is still warranted. 
 In the past decade there has been an increasing awareness of distinct, potentially 
lethal, heritable channelopathic syndromes, which led to a boom of investigation in this field. 
The main objective of this review is to summarize the current knowledge and highlight the 
new discoveries on the clinical characteristics, diagnostic, genetics, pathophysiologic 
mechanisms, therapeutic and prognostic features of CPVT. 
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Resumo  
 
  A Taquicardia Ventricular Polimórfica Catecolaminérgica (TVPC) é uma doença 
hereditária arritmogénica rara, mas altamente letal quando não tratada. Constitui um problema 
de saúde importante, pois pode causar morte súbita em indivíduos jovens e aparentemente 
saudáveis. Caracteristicamente é induzida pelo exercício físico ou stress emocional e 
manifesta-se geralmente como uma síncope acompanhada de taquicardia ventricular, 
polimórfica, bidireccional.  
 A avaliação clínica através de um teste de stress ou monitorização com Holter pode 
facilitar a identificação precoce, ainda que uma investigação genética molecular seja 
fundamental para confirmar  diagnósticos incertos. 
 Estão descritas duas variantes desta doença, uma forma autossómica dominante que se    
deve a mutações no Receptor Rianodínico Tipo 2, e uma forma autossómica recessiva 
associada a mutações na isoforma cardíaca da proteína Calsequestrina 2. Mutações em 
qualquer um destes genes são encontradas em 50-70% dos pacientes com esta síndrome.  
 O mecanismo arritmogênico básico consiste na desregularão da libertação de cálcio 
pelo reticulo sarcoplasmático, causando uma sobrecarga intracelular deste ião e potenciando 
pós-despolarizações tardias e actividade deflagrada. 
 É geralmente aceite que os ß-bloqueadores são a pedra angular da terapêutica crónica 
da TVPC, no entanto, muitos pacientes ainda permanecem sintomáticos; a recorrência e 
mortalidade permanecem elevadas e em muitos casos é necessário um cardioversor 
desfibrillador implantável. Têm vindo a ser descritas inúmeras terapêuticas inovadoras, que 
parecem promissoras, mas ainda é necessária muita investigação nesta área. 
 Nas últimas décadas tem havido uma crescente consciencialização sobre distintas 
canalopatias hereditárias, que são potencialmente letais, o que levou a um desabrochar da 
investigação neste campo. O objetivo principal desta revisão é resumir o conhecimento atual e 
destacar as novas descobertas sobre as características clínicas, o diagnóstico, as bases 
genéticas e fisiopatológicas, a terapêutica e o prognóstico da TVPC. 
Palavras-chave 
 
Taquicardia Ventricular Polimórfica Catecolaminérgica; Pós-despolarização tardia; 
Arritmias Letais; Mutação RyR2; Mutação CASQ2; Tratamento 
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Introduction 
 
 A sudden death is always dramatic, especially when it concerns young apparently 
healthy people. Inherited isolated arrhythmogenic disorders, the so called channelopathies, are 
believed to cause about a third of unexplained deaths in children and adolescents, thus 
traducing a major health problem. Among these disorders, Catecholaminergic Polymorphic 
Ventricular Tachycardia (CPVT), a recently discovered and less known condition, is thought 
to be responsible for approximately 14% of sudden, unexpected death
1, 2
. 
  CPVT is a highly lethal form of inherited arrhythmogenic disease, characterized by 
adrenergically mediated polymorphic ventricular tachycardia
3
. Despite being rare, with an 
estimated prevalence at 1/10.000, the mortality rate of this syndrome reaches up to 50% by 
the age of 30 in untreated individuals, thus making early diagnosis crucial
4
. 
 Clinical evaluation by exercise stress testing and holter monitoring can facilitate early 
identification, even though molecular genetic screening is critical to confirm uncertain 
diagnosis of CPVT.
4
 
 Signs and symptoms usually begin in childhood, and the clinical presentation 
encompasses exercise or emotion- induced syncopal events, seizures or sudden cardiac death 
(SCD), that can  be the first manifestation of the disease, together with a distinctive pattern of 
reproducible, stress related, bidirectional ventricular tachycardia (VT) in the absence of both 
structural heart disease and prolonged QT interval
3, 5, 6
 
 In 1961 Horan and Venables  described the case of a 6 years old Maltese girl, in whom 
emotional upset and effort precipitated unusual rhythms of chaotic heart action , bi-directional 
tachycardia and ventricular fibrillation (VF), in the absence of any cardiovascular 
abnormality
7
. 
  Only 14 years after there was a similar report, when Reid et al. reported a case of 
bidirectional ventricular tachycardia precipitated by effort and emotional stress in a child with 
no evidence of any structural abnormality of the heart
8
.  
 The first comprehensive description of CPVT was provided in 1995 by Leenhardt et 
al., who described a 7 years follow up of 21 children suffering from stress or emotion induced 
syncope, with no evidence of structural heart disease and normal QT interval. It was the first 
time the term CPVT was used, but no genetic analysis was reported, despite a family history 
of syncope or sudden death in seven patients suggesting a genetic origin for this syndrome 
5
. 
 In 1999, Swan et al. described an arrhythmic disorder mapped to the chromosome 
1q42-q43 causing an exercise induced malignant polymorphic ventricular tachycardia in 
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structurally normal hearts; however this study failed to find any mutations or polymorphisms, 
but pointed Ryanodine Receptor-2 (RyR2) as a candidate target for gene mutation
9
. Two 
years latter Priori et al. demonstrated that RyR2 gene mutations are in fact responsible for an 
autossomal dominant form of CPVT
10
 (CPVT1). In the same year, Lahat et al. showed that a 
mutation in the gene for calsequestrin 2 (CASQ2) was the cause of a rare autosomal recessive 
form of CPVT
11
 (CPVT2).  
  More recent studies showed that in approximately 50 to 70% of patients with CPVT a 
mutation in RyR2 or CASQ2 was identified
3, 12
. Mutations in these two genes destabilize the 
RyR2 Ca2+ release channel complex in sarcoplasmatic reticulum (SR) and result in 
spontaneous Ca2+  release, leading to intracellular accumulation of this ion which potentiates 
delayed afterdepolarizations (DADs) and triggered activity
3, 5, 13-15
.  
 Traditionally, adrenergic ß-blockers and implantable cardioverter defibrillator (ICD)  
have been used to treat patients with CPVT, either symptomatic or asymptomatic and can 
substantially decrease the arrhythmia burden and mortality despite being less than ideal 
treatments
16
. Other drugs (i.e. verapamil, flecainide, propofenone, dantrolene), and other 
therapeutic approaches (i.e. left sympathetic denervation and pulmonary vein isolation) have 
been recently proposed and seem promising
17, 18
.  
 During the past decade there has been an increasing awareness of distinct, potentially 
lethal heritable channelopathic syndromes as they are related to SCD in infants and children. 
The aim of this review is to highlight and summarize the current knowledge on the clinical 
characteristics, diagnostic, genetics, pathophysiologic mechanisms, therapeutic and 
prognostic features of CPVT, a primary electrical heart disease characterized by severe 
arrhythmias in young patients with apparently normal hearts
3
. 
 
 
 
Material and Methods 
 
 This monograph was based on a literature search using the databases: PubMed, Scopus 
and ISI Web of Science. The former was based on research of MeSH terms 
Catecholaminergic Polymorphic Ventricular Tachycardia, to search for articles without any 
restriction by type of article, author or publication year. The present research was finished on 
14
th 
October 2011. 
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Clinical Manifestations 
 
 The first clinical manifestation of CPVT is usually a syncope or cardiac arrest 
triggered by emotional or physical stress or while swimming. Other manifestations include 
palpitations, dizziness and convulsions
3, 5
. In more than a third of cases syncope is associated 
with seizure, thus explaining delays in diagnosis as often the initial treatment is an anti- 
epileptic drug. Increasing evidence reinforces that SCD can be the first manifestation of this 
disease
6
. 
 In the first population of CPVT patients described in 1995 by Leenhardt et al. the 
mean age at first event was 7.8 (±4) years ,which is remarkably similar to the results of a 
recent study from Priori et al. that reported a mean age of presentation of 8 (±2) years
3, 5
. The 
pioneer study of Leenhardt et al. also showed a clear relationship between the age of first 
syncope and the severity of the disease, concluding that the earlier the first syncope occurred 
the worse was the prognosis. Nonetheless SCD before the age of 10 was extremely rare , fact 
that can be explained by the rarity of true VF in small size hearts
5
. 
 Patients often have an unremarkable resting electrocardiogram (ECG), without QT 
prolongation, atrioventricular conduction defects or Brugada-like ST/T- segment pattern; 
cardiac imaging examinations are also normal
3, 5
. Therefore, as syncopal events occur in 
otherwise healthy children with a normal cardiac examination, the diagnosis is frequently 
missed unless an exercise stress test or holter is performed to document the arrhythmia. 
During this long delay, between the first symptom and the diagnosis, the patients are 
obviously under a high risk of sudden death
6
. 
 According to Nian et al., the correct diagnosis is established after an average delay of 
2 years from the first syncope, and frequently the cardiac events are considered vasovagal 
events or syncopal events caused by neurologic factors. This group estimated (based on a  
population of 60 probands, which is so far the largest population of CPVT reported in the 
world) that 23% of the probands came to the clinical observation for stress induced cardiac 
arrest, 72% for documentation of polymorphic or bi-directional VT, and 5 % for stress 
induced syncope. The study performed by this group also demonstrated that 62% of all 
sudden cardiac death occurred as the first manifestation of CPVT
19
. 
 Among patients with mutations in the RyR2 gene the clinical presentation is even 
more varied and, importantly, 20% show no ventricular arrhythmia during stress test and are 
completely asymptomatic. In this healthy carrier group there is a predominance of females 
(80%) thus pointing male gender as a risk factor for cardiac events
3
. 
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Diagnosis and ECG Pattern 
 
 Collecting a careful clinical history is always essential in the approach to any patient. 
In the particular setting of an arrhythmogenic disorder resembling CPVT it is crucial to 
establish the relationship between syncope and physical activity or stress; a detailed family 
history, including questions about any SCD in the family and unexplained syncope, is also of 
major interest, as approximately 30% of CPVT patients have a positive family history of 
stress – related syncope, seizures or SCD 3, 5, 20. 
 As already stated, it is usual that CPVT patients have normal physical examination, 
normal resting ECG, normal structure in the echocardiography and normal 
electrophysiological studies, thus making the diagnosis easily overlooked
3, 5
. Nonetheless, 
some recent investigations have shown that patients with CPVT may have sinus bradycardia 
and prominent U-waves in resting ECG, but there is no general agreement on this issue
21, 22
.  
 The most reliable way to diagnose CPVT is a standardized exercise stress test 
21, 23-25
 
that induces ventricular arrhythmias when the sinus rate exceeds an individual threshold, 
usually at rates of 110-130 bpm 
23, 25
. It is advisable to perform the exercise stress test with a 
defibrillator readily available in case a VT degenerates into VF 
26
 (Figure 1). 
 The arrhythmias become more complex when the sinus rate further increases and 
consist of scattered premature ventricular complexes, couplets, bigeminy and bidirectional or 
polymorphic VT , often appearing in this order
5, 9
.  
 Bidirectional VT is characterized by the R-wave axis rotation  of 180 ° from stroke to 
stroke
3
 and is also a typical finding in patients with digitals intoxication and heart failure, both 
states with increased intracellular Ca2+ concentration
19, 27
.  
 Intravenous infusion of adrenaline can also induce progressive ventricular arrhythmias 
and is mainly used to diagnose CPVT in patients with contraindications for exercise
3, 5, 21, 23, 
25
. 
 The arrhythmias can also be detected during Holter monitoring, especially in those 
where the arrhythmias are mainly triggered by emotional stress 
26
.  
 For the CPVT diagnosis it is necessary to exclude structural heart disease and 
electrolyte abnormalities as well as the use of drugs known to trigger arrhythmias 
20
.  
 Important differential diagnosis to be considered are vasovagal or neurocardiogenic 
syncope, epilepsy/seizures, hypertrophic cardiomyopathy, arrhythmogenic right ventricular 
cardiomyopathy, long QT syndrome, Andersen-Tawil syndrome and Brugada syndrome. 
Resting ECG, echocardiography, tilt testing, electroencephalogram and possibly 
10 
 
electrophysiological studies with flecainide/ajmaline can be useful for differentiation of these 
aetiologies 
2
. 
 Diagnosis of CPVT can be verified by means of genetic engineering, by identifying 
precise mutations that have been associated with this syndrome. Post-mortem analysis is 
relevant in SCD in children and young adults, when no cause of death is found at the autopsy. 
This may be important to get an explanation of the death and to discover other family 
members who may be at risk 
20
. 
 
 
Figure 1- Holter electrocardiogram recorded during an exercise-related syncopal episode in a young girl with 
CPVT showing a bidirectional VT degenerating into self-limiting VF. (From Richter et al.28, with permisson.) 
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Pathophysiology of  Arrhythmias 
 
Genetic Basis 
  
 Since the initial descriptions of CPVT, a familial transmission was reported in about 
30% of cases of this disease, fact that conducted to exploration of its genetic basis 
19
. 
 Genetic investigations have identified two variants of CPVT: an autosomal dominant 
form (CPVT1), associated with mutations in the gene encoding the RyR2 and a much less 
common recessive form (CPVT2), associated with homozygous mutations in the gene 
encoding the cardiac isoform of CASQ2, this latter being a simple explanation for sporadic 
CPVT cases without familial involvement 
29
.  
 However, in about 30 to 50 % of the patients, it was not identified any disease-causing 
mutation on either RyR2 or CASQ2 genes, therefore making it likely that other CPVT related 
genes exist despite not yet discovered
3
.  
 Importantly, in 2002, Priori et al. demonstrated that the natural history of the disease 
does not significantly differ between affected individuals with or without RyR2 mutations. 
However, 90% of patients with nongenotyped CPVT were females and became symptomatic 
later in life, i.e.20 ±12 years vs. 8 ± 2 years in patients with RyR2- associated CPVT
3
. 
 Recently, cases of mosaicism in CPVT were described
30, 31
 and this can lead to tragic 
consequences, since silent mutation carriers are at risk for arrhythmic events
12
. The 
manifestations and severity of symptoms of the disease in a carrier of somatic and germline 
mosaicism depend on several aspects, such as the degree of mosaicism and the gene involved 
32
. 
  Roux-Buisson et al. reinforced the fact that the possibility of germline mosaicism in 
asymptomatic parents justifies systematic genetic screening of sibling of a sporadic proband, 
even if the standard methods failed to clearly detect the mutation in the parents
31
.
 Additionally, germline mosaicism also carries a risk of recurrence that despite thought 
to be <1% should not be underestimated
31
 
  
RyR2 Mutations 
 
  In approximately 50% 
3, 27
 to 70%
33
 of the patients with CPVT,  mutations on RyR2 
gene can be identified, and they have a mean penetrance of 80%
33
. RyR2 is a tetrameric 
12 
 
intracellular Ca2+ release channel located in the SR and required for cardiac excitation-
contraction coupling. 
 The identified mutations are mostly single-base-pair substitutions leading to the 
replacement of highly conserved amino acids 
34
, and appear to cluster in three hot spot regions 
of the gene : N-terminus (77-466), the central domain (2246-2534) and the C- terminal pore 
region (3778-4959) 
15
. 
 In 1999, Swan et al. demonstrated for the first time, the linkage of CPVT to 
chromosome 1q42-q43
9
.Two years later, RyR2 mutations were identified in four families 
with the typical pattern of CPVT and history of sudden cardiac death, thus confirming RyR2 
as a causative gene for autossomal dominant CPVT form
10
.  
 This data has been shortly after confirmed by many other investigators, and a huge 
number of mutations on the RyR2 gene were identified since then. Those mutations are 
summarized on Table 1 (see appendix). 
 Nowadays, the knowledge about RyR2 mutation is growing really fast and this could 
be illustrated by the fact that just in the first 6 months of the present year of 2011, three new 
RyR2 mutations were described. 
 Lobo et al. described a very severe form of CPVT caused not by a simple amino acid 
substitution, but, by the entire deletion of the exon 3 of RyR2 gene that encodes secondary 
structure elements that are crucial for folding of the N-terminal domain
35
. 
 Kazemian et al. revealed a novel missense mutation in exon 90 of the ryanodine 
receptor gene resulting in substitution of arginine for serine at residue 4153 (S4153R)
36
 
(Figure 2). 
 Meli et al. reported a novel CPVT-linked RyR2 mutation that results in the 
substitution of cysteine for glycine at position 230, RyR2-G230C, located in the “hot-spot” N-
terminal domain of cardiac RyR2
37
. 
 
 
13 
 
 
 
Figure 2- Schematic representation of the cardiac RyR2 channel topology. Mutations cluster in RyR2 and are 
distributed in 3 “hot-spot” regions, called domains I (N-terminal), II (central), and III (channel region). It is also 
identified the location of the novel S4153R substitution missense mutation. (Adapted from Kazemian et al. 36, 
with permission.) 
  
 
CASQ2 Mutations 
 
 Identification of CASQ2 mutations is a much more rare event and occurs in only about 
2% 
3, 27
 to 7%
33
 of the patients with CPVT.  
 In 2001, Lahat et al. published the sequentiation of the CASQ2 gene (Figure 3) and 
described a missense mutation, in a highly conserved region of CASQ2, associated with an 
autossomal recessive form of CPVT, thus confirming CASQ2 (the major Ca2+ reservoir within 
the SR of cardiac myocytes and a part of RyR2 complex) as a causative gene of CPVT
11
. 
 It was classically accepted that CASQ2 mutations were responsible for a recessive 
form of CPVT and thus only homozygous carriers would manifest pathologic clinical 
phenotype, while heterozygous carriers would be silent
3
. However, in 2006, Di Barletta et al. 
14 
 
reported the first CPVT patient carrying two distinct CASQ2 mutations, demonstrating that 
compound heterozygous mutations also lead to CPVT phenotype
38
. 
 Until now, a limited number of CASQ2-genotyped patients have yet been reported, 
therefore a significantly smaller number of CASQ2 mutations where identified, when 
comparing to RyR2 mutations. The former are summarized on Table 2 (see appendix). 
  Despite CASQ2 related CPVT still awaits more clinical and genetic data, the research 
in this area is flourishing, as revealed in a study published in 2011  by Roux-Buisson et al., 
that reported the first splicing abnormalities in CASQ2 caused by intron mutation 
(c.939+5G>c) or synonymous change (c.381C>T, p.Gly127Gly). This investigation also 
reported two single nucleotide deletions (c.546delT; c.03delA) and three single nucleotide 
substitution (c.320-24>g; c.7.37+1g>A; c.101+1G>A), thus contributing significantly for a 
better understanding of CASQ2 related CPVT genetic mechanisms 
39
. 
 
 
 
 
Figure 3  
a- Physical map of the CPVT locus. Landmark genes are shown as red boxes with their HUGO nomenclature 
symbols. Microsatellite markers are indicated by arrows pointing to their exact position on the genomic bar map.  
b- Expanded view of a 75-kb segment, showing the genomic organization of the CASQ2 interval. The interval is 
covered by two genomic clones that have 5-kb overlap. AL449264 contains the first four exons, and AL450389 
contains the other seven exons, depicted by blue boxes. The lengths of the exons are shown below the boxes, and 
those of the introns are shown above the line. The translation-initiation site and the stop codon are indicated. 
(From Lahat H et al.11, with permission). 
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Ionic and Cellular Mechanisms 
 
 The plateau phase of ventricular action potential is the result of balanced Ca2+ influx 
trough the L-type Ca2+ channels (LTCC) and K+ efflux (critically depending on the delayed 
rectifier K+ channels: IKr (hERG) and IKs (KCNQ1/KCNE1)
40, 41
.  
 Following an action potential, a small influx of Ca2+ through the L-type voltage 
dependent channels, rises intracellular Ca2+ concentration, thus activating the RyR2 Ca2+  
release channel located in the SR, a mechanism known as Ca2+ induced Ca2+  release 
40
. 
Calcium ions will then bind to the troponin complex and activate the contractile apparatus 
40, 
41
. 
 Relaxation of the cardiac muscle will follow Ca2+ removal from the cytosol, in the 
rabbit, cat, dog, guinea pig, and humans most of the Ca2+ (70%) is recycled into the SR via SR 
Ca2+ -ATPase (SERCA), while 28% is extruded from the cell through Na+ / Ca2+  exchanger 
(NCX), about 1% is removed by the sarcolemmal Ca
2+
-ATPase, and an additional 1% is 
transported into the mitochondria 
42, 43
. Reduction of cytosolic calcium [Ca2+] to the basal level 
allows Ca2+ dissociation from the myofilaments and mechanical relaxation. 
 The ability to store a large amount of Ca2+ into the SR is due to the activity of  CASQ2, 
a selective Ca2+ buffering protein, located in specialized areas of the SR, where it forms 
junctions with the sarcolema of the myocytes 
43, 44
.  
 Further, CASQ2 forms a quaternary complex with the RyR2 channel and with the 
junctional SR membrane proteins Triadin-1 and Junctin, thus being also an important 
regulator of RyR2 channel function apart of its role for global Ca2+  binding and buffering 
45
. 
 It is easy to understand that, playing a central role in the contraction/relaxation cycle 
of the heart, a tight regulated release of Ca2+ from the SR is essential to maintain normal 
cardiac activity 
40, 42, 44
 (Figure 4). 
 Deregulation of function of either RyR2 channel or CASQ2 will, as one can expect, 
destabilize the mechanism of Ca2+ intracellular currents from the SR resulting in spontaneous 
excessive release of this ion 
43
.   
 When cardiac cells are overloaded with Ca2+, Ca2+ sparks (the ascent and descent in [Ca2+] 
during a cardiac cycle is called Ca2+ transient; an elementary unit of Ca2+ release from the SR, generated 
by Ca2+  influx from a single LTCC and adjacent RyR2, is regarded as calcium spark) lead to 
propagating Ca2+ waves that potentiate DADs, which in turn can lead to triggered activity and 
bidirectional/polymorphic VT, mimicking the toxic effect of digitals 
13, 43
 (Figure 5). 
16 
 
 Delayed afterdepolarizations are enhanced by adrenergic stimulation, which can 
explain why CPVT manifest during stress 
10, 43
.  
  
 
 
Figure 4- Protein complexes, cardiomyocyte architecture, and intracellular organelles involved in excitation–
contraction coupling. (From Watanabe et al. 43 with permission.) 
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a- Intracellular calcium overload caused by RyR2 and CASQ2 mutations and potentiated by B-adrenergic 
stimulation. (Adapted from Farwell et al.46, with permission.) 
b- Delayed afterdepolarizations caused by intracellular calcium overload.  
c- Polymorphic Ventricular Tachycardia related to delayed afterdepolarizations as showed in b. 
 
 
RyR2 Mutations and CPVT 
 
 There are various proposed mechanisms underlying leaky RyR2 channel as a result of 
RyR2 mutations. 
  Open probability of RyR2 channel is increased by Ca2+ concentration in the cytosol, 
and spontaneous Ca2+ release by RyR2 channel occurs when Ca2+ concentration reaches a 
certain level (the Ca2+ release threshold) 
47
.   
 Meli et al. recently showed that some RyR2 mutations (including RyR2-S2246L, 
RyR2-R2474s, RyR2-R4497c, RyR2-P2328S, RyR2-Q42o1R and RyR2-V4653F), linked to 
Figure 5 
18 
 
CPVT, shift the sensitivity for cytosolic Ca2+ dependent activation of the channel, allowing the 
channel to be opened even at low diastolic levels of cytosolic Ca2+, thereby causing a diastolic 
SR Ca2+ leak. Importantly, this alteration in sensitivity was only observed after PKA 
(phosphokinase A) phosphorylation, condition that mimics the effect of exercise or stress on 
the channel activity
37
. More recently, it was proved that caffeine also has the ability to lower 
the threshold at which luminal  Ca2+
 
can activate spontaneous opening of RyR2 channel 
48
. 
 Normally, when the cytosolic Ca2+ level rises too high, there is a Ca2+ dependent 
inhibition of RyR2 channels, stopping the leak of Ca2+ from the SR. Thomas et al. reported 
that RyR2-L433P and RyR2-N23861 mutant channels exhibit impaired sensitivity to Ca2+ 
dependent channel inhibition
49
. 
 Investigations using the CPVT mutant model RyR2-R2474S suggests that CPVT 
linked mutations induce defective interdomain conformational changes that destabilize the 
closed state of RyR2 channel and enhance the probability of opening
50
. 
 The importance of SR Ca2+ load in the genesis of Ca2+ waves and arrhythmias is also 
supported by the investigations of Sedej et al. With the same mice model (RyR2-R4496) they 
demonstrated that, using ouabain (an inhibitor of Na
+
/K
+
-ATPase) to produce Na+ dependent 
rise of SR Ca2+ load (Na
+
 - Ca
2+
 exchange), it is possible to reproduce the Ca2+ waves leading 
to arrhythmias as those seen in CPVT patients 
51
. 
  
CASQ2 Mutations and CPVT 
 
 In what concerns to Calsequestrin 2 mutations, the best described mechanisms leading 
to CPVT is the reduction or complete loss of activity of this selective Ca2+ buffering protein 
43
. 
Several studies using CASQ2 null mice have shown that a modest reduction of calsequestrin 
protein is sufficient to increase arrhythmia susceptibility even in the absence of any change in 
other SR proteins
41, 43
. 
 Mutations in CASQ2 gene can also impair interaction of Calsequestrin with RyR2 
protein complex, despite a normal amount of this protein, thus impairing the regulation of Ca2+ 
release from the SR. A good example is the point mutation D307H that leads to a profoundly 
altered conformation of calsequestrin that no longer responds normally to Ca2+ and fails to 
bind to Triadin and Junctin 
52
. 
 A pioneer work from Eckey et al., showed that CASQ2 is also a functional modulator 
of the hERG K
+
 repolarizing channels and that some CASQ2 mutants (including R33Q and 
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F189L) show changes in modulations of these channels leading to abnormalities in the plateau 
phase of the cardiac action potential
41
. 
  Finally, the  most recent study about the way CASQ2 mutations lead to CPVT 
suggests that some mutations modify calsequestrin behavior, including folding (L167H 
mutation), aggregation/ polymerization (R33Q mutation) and selectivity towards Ca2+ (D307H 
and P308L mutations
44
. 
 
Effects of ß -Adrenergic Stimulation 
 
 Sympathetic stimulation of ß-adrenergic receptors leads to activation of adenylate 
cyclase through a Gs protein, ultimately inducing cyclic AMP synthesis. The rise in cyclic 
AMP activates PKA to phosphorylate its target proteins, mediating the well known inotropic 
and lusitropic sympathetic effects. Phosphorylation of LTCC increases Ica currents and 
Phospholamban phosphorylation increases Ca2+ uptake into the SR, enhancing relaxation and 
increasing [Ca2+] SR 
27
.  
 RyR2 phosphorylation leads to its dissociation of Calstabin 2 (also called FKBP12.6, a 
channel stabilizing protein that binds to RyR2 and stabilizes it in a closed state), thus 
facilitating Ca2+ release from the SR 
27
. Phosphorylation of Calstabin 2 by PKA further 
reduces its ligation to RyR2, resulting in increased Ca2+ leak 
43, 53
. 
 One of the most recent publications about the mechanisms leading to CPVT aimed to 
further clarify why arrhythmias only develop during ß-adrenergic stimulation. Mice carrying a 
human CPVT mutation (RyR2-R4496) were stimulated with isoprotenerol (ß1 and ß2 agonist) 
and it was verified that the Ca2+ load of SR and the diastolic Ca2+ waves significantly rose, 
which typically reproduced the  CPVT pathophysiology. Those data allowed several authors 
to postulate that ß-adrenergic stimulation, besides lowering the threshold for RyR2 channel 
opening, as already stated, also contributes to the arrhythmias by raising the SR Ca2+ load
54
.  
 Cumulatively these mechanisms result in increased RyR2 open probability and Ca2+   
leak, thereby explaining increased predisposition to Ca2+ induced arrhythmia during 
sympathetic stimulation. 
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Current and Future Therapies for CPVT 
 
  Since the first descriptions of the disease it has been recognized that the first step in 
the approach to a patient with CPVT should be: careful information about the importance of 
the therapeutic compliance; advising against participation in competitive sports and clarifying 
the contraindication to use sympathomimetic agents
5, 16
.  
 Until now there is a lack of information to identify patients with such a low risk of 
arrhythmic events that would make treatment unnecessary. Therefore, all  phenotypically and/ 
or genotypically diagnosed patients are considered at risk and should receive appropriate 
therapy
16
. 
 CPVT therapy is challenging because it interferes with excitation-contraction coupling 
and must therefore be compatible with adequate contractility and physiological electrical 
activity.  
 
Acute Treatment 
 
 In the acute management of a sustained VT or VF, in the setting of CPVT, the most 
critical aspect is to recognize that it concerns in fact a CPVT patient and thus standard 
adrenaline infusion, for resuscitation, should be avoided 
16
. 
 Intravenous ß-blocker therapy is considered as Class I recommendation and should be 
the first choice for acute management. General anesthesia can be used as last resort when 
there is no response to ß-blockers agents 
4
. 
 Despite the general previous statements, acute treatment of polymorphic VT as 
provided in the ACC/AHA/ESC guidelines
4
 could be summarized as follows: 1) if 
hemodynamic compromise is present, immediate direct current cardioversion should be 
performed; 2) for recurrent polymorphic VT, intravenous beta blockers should be 
administered, especially if ischemia is suspected or cannot be excluded; 3) for recurrent 
polymorphic VT in the absence of congenital or acquired QT interval prolongation, 
intravenous amiodarone should be administered. 
 Adenosine triphosphate and verapamil can be considered as future options for the 
management of these acute situations, since they were effective terminating adrenaline-
induced VT during a recent CPVT electrophysiological study 
55
. 
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Chronic Treatment 
 
ß- Blocker Therapy 
 
 The relationship between VT and ß-adrenergic activation, as well as the efficacy of ß-
blocker therapy were recognized since the pioneer clinical descriptions of CPVT 
5, 7, 8
. 
  In the first comprehensive CPVT series published by Leenhardt et al. in 1995 it 
became apparent that ß-blockers agents were the most effective drug therapy reducing 
ventricular arrhythmias during exercise testing or Holter monitoring, as well as preventing 
arrhythmic events. Particularly, the efficacy of nadolol was documented in all the patients, 
both clinically and on ECG studies 
5
. 
 In subsequently published series the results have been variable, with the range of 
arrhythmic events on ß-blocker therapy (acebutulol, atenolol, bisoprolol, metoprolol, nadolol, 
or propanolol) ranging from 0 to 55% in 10 studies conducted until now (including between 
14 and 101 young patients, with a follow up duration between 1.8 to 7.9 years). It was also 
reported a proportion of nearly fatal and fatal arrhythmic events ranging from 0 to 40% and 2 
to 20% respectively 
3, 5, 9, 12, 21, 23, 24, 56-58
 .    
 Despite these different results it is generally accepted that ß-blocker agents are the 
cornerstone of chronic CPVT therapy
4
. However, inadequate response or an “escape” 
phenomenon, is not uncommon; recurrence and mortality remain high and many patients 
require an ICD
27
 fact that conducted to the exploration of other  management options. 
 
 
Other Options for Chronic Treatment 
 
 Implantable cardioverter-defibrillators  
  
 Class I recommendation was given for implantation of an ICD in addition to ß-blocker 
therapy in CPVT patients who were survivors of aborted cardiac arrest
4
. Patients with CPVT 
who develop sustained VT or syncope (for which causes other than VT are excluded) while 
taking a beta blocker are likely to be at higher risk of future SCD. Electrophysiological testing 
is generally not helpful in patients with CPVT since the arrhythmia is usually not inducible 
with programmed ventricular stimulation. In such patients, ICD placement is a reasonable 
approach (class II recommendation according the 2006 ACC/AHA/ESC Guidelines for 
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Management of patients with Ventricular arrhythmias and the Prevention of Sudden Cardiac 
Death
4
. In 2008 ACC/AHA/HRS Guidelines For Device-Based Therapy of Cardiac Rhythm 
Abnormalities, reinforced those indications
59
. 
 Nonetheless, ICDs have been implanted in a more liberal way before and after these 
guidelines were published. This might be a dangerous practice, because ICDs can have a 
harmful effect in CPVT patients. There were reported cases showing that appropriate and 
inappropriate ICD shocks can trigger catecholamine release, subsequently resulting in 
multiple shocks, arrhythmic storm, and death. Thus, the implantation of an ICD does have a 
potential proarrithmic effect
60-62
 . 
 More recently , the Hearth Rhytm UK Statement on Clinical Indications for ICD in 
adult Patients with Familial Sudden Cardiac Death concurred with the previous 
recommendations, while adding left sympathetic denervation (LSD) as a therapeutic 
consideration before ICD implantation
63
.  
 
  Verapamil 
 
 The rationale for treating CPVT patients with a L-type Ca2+ channel blocker is easy to 
accept, because, as it was already stated, Ca2+ influx through the L-type Ca2+ channels, triggers 
Ca2+-dependent Ca2+ release thought defective or inappropriately regulated RyR2 channel, 
leading to the ionic and electrical abnormalities that characterize CPVT 
38
. 
 Three recent studies 
64-66
 have evaluated and proved a beneficial effect of verapamil in 
treating CPVT selected patients, but just in combination with ß-blocker therapy, thus the true 
role of verapamil has not yet been well assessed. However the fact that in none of these three 
studies was reported a negative ionotropic effect of verapamil is a very positive indication. 
 
 Flecainide 
  
 Recently, it was discovered that the antiarrhytmic agent and Na+ channel blocker 
flecainide directly blocks RyR2 channels, prevents RyR2-mediated premature Ca2+  release, 
and suppresses triggered beats in myocytes isolated from mouse hearts lacking calsequestrin, 
an animal model of CPVT
67
. This effect is not mediated by Na+ channel block, the 
conventional mode of action thought to underlie flecainide activity, but rather can be 
attributed to open state block of RyR2 channels ( that is, flecainide directly targets the 
molecular defect responsible for the arrhythmogenic Ca2+  waves that trigger CPVT in vivo )
68
. 
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  Additionally, it was also reported that flecainide completely prevented CPVT 
arrhythmic events in two human subjects who remained highly symptomatic on conventional 
drug therapy, indicating that it might be promising in the management of CPVT 
67
. 
 The efficacy of flecainide was also retrospectively evaluated in a relatively large 
multicenter study including 33 CPVT patients, refractory to ß-blocker therapy, alone or 
combined with Ca2+ channel blockers. The results were encouraging, as in 76% of the patients 
flecainide (the median daily dose in responders was 150 mg - range 100 to 300 mg; follow-up 
12-40 months) suppressed exercise induced ventricular arrhythmias (partially or completely), 
and importantly, proarrhytmia as a result of flecainide was not observed 
17
.  
 Currently is ongoing a clinical trial comparing ß-blocker therapy alone and with 
flecainide, to test the effect of flecainide prospectively [more information can be accessed at 
(http:77clinicaltrials.gov:NTC01117454)].  
 
 Left sympathetic denervation  
 
  LSD (also known as left stellate cardiac ganglionectomy) consists in a transection of 
the left sympathetic chain at the levels of T1 to T5. Moss et al. described it for the first time in 
1971 for the management of Long QT syndrome, and since than it has been used, with good 
results, in patients with this syndrome that are refractory to other therapies, fact that 
encouraged its use in other arrhythmogenic diseases
69
. 
 In CPVT the sympathetic nervous system plays a crucial role in the genesis of life-
threatening arrhythmias. Thus, it was predictable that LSD would increase ventricular 
refractoriness threshold 
70
. 
 Since LSD was first applied to CPVT patients refractory to ß-blocker therapy and 
receiving recurrent ICD discharges, two case series 
71, 72
 and some isolated cases 
73, 74
 were 
reported, using video-assisted thoracoscopic LSD, with excellent results. 
 Unlike ß-blockers, LSD does not impair the physiological increase in ventricular 
function with exercise, neither decreases the resting ventricular function, because the 
contralateral sympathic chain is intact
70
.  
 The drawbacks of LSD include rare potential complications such as transient or 
persistent Horner´s syndrome and pneumothorax, and the fact that it is not a universally 
available procedure , requiring an expert surgeon and delicate instrumentation
75
. 
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 Recently, it has been postulated that LSD should be performed simultaneously with 
ICD implantation, as it does not increase the length of hospital stay or procedure related 
mortality, and can prevent the potential proarrhytmogenic effect of ICD shocks 
18
. 
 
Future Developments 
 
 Apart from the previously described options for chronic management, that are already 
being introduced into clinical practice, there are also some other treatment modalities that 
have more recently being reported, with good results, in some selected cases of CPVT, and 
therefore may soon become available in a larger scale.   
 
 Propafenone 
 
 Propafenone, a class Ic antiarrhytmic agent that also contains ß-receptor blocking 
properties was clinically proved to be effective in suppressing appropriate ICD shocks and 
exercise induced CPVT in a Turkish patient, who remained severely symptomatic after 
maximal drug therapy and LSD, and thus may be an ideal drug in CPVT management. 
 Propafenone was attempted because flecainide is not available in Turkey, and 
subsequent in vitro and in vivo studies showed that propafenone has similar RyR2 blocking 
properties as flecainide
76
. 
 
 Dantrolene  
 Dantrolene proved recently to prevent exercise and adrenaline induced ventricular 
arrhythmias in a CPVT mouse model
77
. This action is thought to be due to ligation and 
stabilization of the mutated RyR2 
78
 and restoration of the affinity of calmodulin to bind 
RyR2
79
. Dantrolene also improved substantially the contractile function in pacing induced 
failing hearts, fact that is quite advantageous for its clinical use
78
. 
 
 Calmodulin kinase II inhibition 
 
 The Calmodulin kinase II (CAMKII) inhibitor KN93 was proven to completely 
prevent catecholaminergic-induced sustained VT in RyR2 mutant mice. Mechanistically 
CAMKII inhibition acts on several elements of the excitation-contraction coupling cascade, 
including attenuation of SR Ca2+ leak and blunting catecholaminergic-mediated SERCA 
activation, and thus may represent a novel therapeutic target for patients with CPVT 
80
. 
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 Magnesium supplementation 
 
 The nonspecific RyR2 blocking effect of Mg2+ was rather remarkable in CASQ2 
mutant mice and this electrolyte has a proven added value in numerous types of ventricular 
arrhythmia. Katz et al.
27
 suggest that preserving normal levels of Mg2+  and supplementations 
to increase intracellular Mg2+ should be recommended to CPVT patients unless otherwise 
contraindicated. 
 
 Selective serotonin reuptake inhibitors 
 
 Chen et al. described recently the case of a patient, in whom, the selective serotonin 
reuptake inhibitor paroxetine, combined with ß-blocker therapy, prevented ICD shocks during 
two years, while the patient had received two shocks in the previous 6 months, when treated 
with ß-blocker agents alone. However the exact mechanism underlying this action remains 
unclear
81
. 
 
 Pulmonary vein isolation 
 
 Pulmonary vein isolation was performed in a patient with CPVT that received 
inappropriate ICD shocks due to atrial fibrillation. This procedure did not just reduce this 
supraventricular arrhythmia, but also, decreased the number of VTs and premature ventricular 
complexes on Holter registration
82
. 
 Pulmonary vein isolation may have decreased the sympathetic enervation, and thus, 
may be an additional treatment option in patients resembling the case described.  
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Genetic Testing 
 
 Genetic testing is of major interest since CPVT is one of the rare cases when lifestyle 
modification and even drug therapy appear to be indicated even in the absence of clinical 
phenotype, based only on genetic diagnosis
83
. 
 RyR2 is the prevailing candidate gene, and thus, in a cost-contained environment, 
should be the first gene to be screened, unless disease transmission is incompatible with 
autosomal dominant inheritance. Screening of CASQ2 gene is warranted after excluding 
RyR2 mutations, in particular, when CPVT is familial and the history is suggestive, or 
possibly compatible with recessive inheritance (i.e., consanguinous, similar ethnic 
background, etc). Because RyR2 is a huge gene, a cost effective strategy was developed 
restricting the screening to 20% of gene length but covering the regions encompassing 95% of 
the mutations described until now 
84
. 
 If the genetic study is negative for both RyR2 or CASQ2 gene mutations, screening 
for Long QT genes, starting with KCNJ2, may be considered, particularly in females with 
bidirectional/polymorphic VT
85
. 
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Conclusions 
 
 CPVT is a rare, although highly lethal, inherited arrhythmogenic disease. Affecting 
predominantly young otherwise healthy subjects it represents an important health burden.  
 Patients experience catecholamine induced ventricular arrhythmias with modest 
exercise or emotional stress, fact that creates a significant limitation to their normal lives.  
 SCD can be the first presentation and thus early diagnosis and institution of therapy 
can drastically change the prognosis and be lifesaving. 
 Just in the last 12 months 58 articles were published, presenting novel information on 
this disease, thus, it seemed important to summarize the current knowledge and highlight the 
new discoveries on the clinical characteristics, diagnostic, genetics, pathophysiologic 
mechanisms, therapeutic and prognostic features of CPVT, constituting this, the main 
objective of this review. 
  Since the first case reports of this disease, the knowledge about clinical characteristics 
and diagnosis has not improved a lot, as proved by the fact that a definitive CPVT diagnosis is 
nowadays still made with an average delay of about two years. 
 In what concerns to understanding the pathophysiology of the arrhythmias, numerous 
explanations have been proposed, but, since there is often more than one possible 
interpretation of experimental findings, several controversies have evolved and there is still 
no consensus in this field.  There is although general agreement that the base of the electrical 
abnormalities is intracellular Ca2+ overload, which potentiates DADs and triggered activity. 
 The field with more information being published is the genetic basis of CPVT. An 
increasing number of CASQ2 and mainly RyR2 gene mutations have been identified. To date, 
there are more than 100 known mutations in RyR2 causing CPVT1 and 12 CASQ2 mutations 
reported to cause CPVT2. This represents a major advance since, identifying a disease 
causing mutation, not only confirms and refines the clinical diagnosis, facilitating the most 
appropriate behavioral counseling and therapy, but also, creates the possibility of genotyping 
and risk-stratifying family members of the proband. Ilustrating this, the recent description of 
mosaicism in CPVT justifies genetic screening of sibling of a sporadic proband even when 
standard methods fail to detect mutations in the parents. 
 In what concerns to the management of CPVT, the recent advances have also been 
impressive. ß-Blocker agents are still considered the cornerstone of therapy, and ICD 
implantation is recommended for survivors of cardiac arrest but a great number of new agents 
and management procedures have been reported with good results in selected patients.  
28 
 
 The generation of animal models for arrhythmogenic channelopathies is well 
underway, and analyses of these models will continue to provide insights into molecular 
processes leading to various diseases. Ultimately, mouse model lines will offer the potential 
for testing therapeutic approaches that might help combat these disorders. 
 Summing up, CPVT is a recently discovered and not well known disorder; a lot of 
work still remains to be done in order to a better understanding of the ionic and cellular 
arrhythmogenic mechanisms and the genetic subtract of the disease, providing clues for an 
early diagnosis as well as new possible therapeutic targets. In what concerns to the latter, 
specifically tailored therapy for a given molecular defect is still a long way off, but seems a 
promising possibility in the treatment of CPVT. 
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Appendix 
 
 
Table 1- RyR2 Mutations 
 
Nucleotide  
Change  
Amino Acid 
Change  
Mutation  
Type  
Protein  
Domain  
Exon References  
1.1kb 
deletion 
Exon 3 
deletion 
Deletion Amino Terminal 3 Bhuiyan et al 
2007; Medeiros-
Domingo et al. 
2009 
3.6kb 
deletion 
Exon 3 
deletion 
Deletion Amino Terminal 3 Medeiros-
Domingo et al. 
2009 
C184T L62F Missense Amino Terminal 3 Medeiros-
Domingo et al. 
2009 
C230T A77V Missense Amino Terminal 3 d'Amati et al. 
2005; Medeiros-
Domingo et al. 
2009 
A241C M81L Missense Amino Terminal 3 Medeiros-
Domingo et al. 
2009 
C493T P164S Missense Amino Terminal 8 Choi et al. 2004; 
Medeiros-
Domingo et al. 
2009 
G506A R169Q Missense Amino Terminal 8 Hsueh et al. 
2006; Medeiros-
Domingo et al. 
2009 
C230T A77V Missense Cytoplasmatic 
loop 
3 D'Amati et al 
2005 
G506A R169Q Missense Cytoplasmatic 
loop 
8 Hsueh et al. 2006 
G556A V186M Missense Cytoplasmatic 
loop 
8 Tester et al 2006 
A567T E189D Missense Amino Terminal 8 Davis et al. 2006; 
Medeiros-
Domingo et al. 
2009; Jones et al. 
2010 
G727A E243K Missense Amino Terminal 10 Medeiros-
Domingo et al. 
2009 
T985C F329L Missense Amino Terminal 12 Medeiros-
Domingo et al. 
2009 
C994T R332W Missense Amino Terminal 12 Medeiros-
Domingo et al. 
2009 
G1129A V377M cSNP Amino Terminal 13 Medeiros-
Domingo et al. 
2009 
G1072A G357S Missense Amino Terminal 13 Medeiros-
Domingo et al. 
2009 
C1240T R414C Missense Amino terminal 14 Tester 2005; 
Medeiros-
Domingo et al. 
2009 
C1244G T415R Missense Amino Terminal 14 Medeiros-
Domingo et al. 
2009 
G1259A R420Q Missense Amino Terminal 14 Medeiros-
Domingo et al. 
2009 
G1519A V507I cSNP Amino Terminal 16 Medeiros-
Domingo et al. 
2009 
C1646T A549V Missense Amino Terminal 17 Medeiros-
Domingo et al. 
2009 
- S616L Missense Cytoplasmic loop 19 Marjamaa et al 
2009; Medeiros-
Domingo et al. 
2009 
G2216A R739H Missense Cytoplasmic loop 21 Medeiros-
Domingo et al. 
2009 
G3038A R1013Q Missense Cytoplasmic loop 26 Medeiros-
Domingo et al. 
2009 
- R1051P Missense Cytoplasmic loop 27 Marjamaa et al 
2009; Medeiros-
Domingo et al. 
2009 
C3407T A1136V cSNP Cytoplasmic loop 28 Medeiros-
Domingo et al. 
2009 
C3320T T1107M Missense Cytoplasmic loop 28 Medeiros-
Domingo et al. 
2009 
G5169A E1724K Missense Cytoplasmatic 
loop 
37 Postma et al. 
2005 
G5170A E1724K Missense Cytoplasmic loop 37 Postma et al. 
2005; Medeiros-
Domingo et al. 
2009 
G5509A E1837K Missense Cytoplasmic loop 37 Medeiros-
Domingo et al. 
2009 
A6137G E2045G Missense Cytoplasmic loop 40 Medeiros-
Domingo et al. 
2009 
G6337A V2113M Missense Cytoplasmic loop 41 Tester et al. Heart 
Rhythm 2009;6 
Suppl 1: S137; 
Medeiros-
Domingo et al. 
2009 
G6337A H240R Missense Amino Terminal 10 Tester et al. Heart 
Rhythm 2009;6 
Suppl 1: S137; 
Medeiros-
Domingo et al. 
2009 
- G2145R Missense Cytoplasmic loop 41 Marjamaa et al 
2009; Medeiros-
Domingo et al. 
2009 
A6467G Y2156C cSNP Cytoplasmic loop 42 Medeiros-
Domingo et al. 
2009 
C6504G H2168Q Missense Cytoplasmic loop 42 Medeiros-
Domingo et al. 
2009 
A6548T E2183V cSNP Cytoplasmic loop 42 Medeiros-
Domingo et al. 
2009 
A6647T D2216V Missense Cytoplasmic loop 43 Medeiros-
Domingo et al. 
2009 
C6737T S2246L Missense Cytoplasmatic 
loop 
44 Priori et al. 2001; 
Tester et al 2004 
C6740T S2246L Missense Cytoplasmic loop 44 Priori et al 2001; 
Medeiros-
Domingo et al. 
2009 
C6761T A2254V Missebse Cytoplasmatic 
loop 
44 Postma et al. 
2005 
G6800A R2267H Missense Cytoplasmic loop 45 Tester et al 2007; 
Medeiros-
Domingo et al. 
2009 
G6886C E2296Q Missense FKBP binding 
domain 
45 Medeiros-
Domingo et al. 
2009 
G6916A V2306I Missense FKBP binding 
domain 
45 Laitinen et al. 
2003 
T6919C F2307L Missense FKBP binding 
domain 
45 Berge et al 2008; 
Medeiros-
Domingo et al. 
2009 
G6933A E2311D Missense FKBP binding 
domain 
46 Priori et al. 2002 
- V2321M Missense FKBP binding 
domain 
46 Nishio et al 2008; 
Medeiros-
Domingo et al. 
2009 
C6982T P2328S Missense FKBP binding 
domain 
46 Laitinen et 
al.2001 
  G2337V Missense FKBP binding 
domain 
46 Haugaa et al 
2010  
G7076A R2359Q
(5) Missense FKBP binding 
domain 
 Aizawa et a 2006 
G7158C A2387P Missense FKBP binding 
domain 
47 Bagattin et al 
2004 
A7165C M2389L cSNP FKBP binding 
domain 
47 Tester et al. 
Circulation 
2005; 11; 516.; 
Medeiros-
Domingo et al. 
2009 
C7181G A2394G Missense FKBP binding 
domain 
47 Postma et al. 
2005 
G7202A R2401H  Missense FKBP binding 47 Aizawa et al 
domain 2005 
C7210A R2404T Missense FKBP binding 
domain 
47 Beckmann et al 
2008; Medeiros-
Domingo et al. 
2009 
G7422C R2474S Missense FKBP binding 
domain 
49 Priori et al. 2001; 
A7258T R2420W Missense FKBP binding 
domain 
48 Medeiros-
Domingo et al. 
2009 
G7423T V2475F Missense FKBP binding 
domain 
49 Tester et al. 2005 
- L2487I Missense FKBP binding 
domain 
49 Tester 2005 
C7599G L2534V Missense FKBP binding 
domain 
50 Hasdemir et al. 
2004 
C11332T L3778F Missense Cytosol 83 Priori et al. 2002 
C11636C L3879P Missense Cytosol 86 Tester et al. Heart 
Rhythm 2009;6 
Suppl 1: S137; 
Medeiros-
Domingo et al. 
2009 
C11773G Q3925E Missense Cytosol 87 Tester et al. Heart 
Rhythm 2009;6 
Suppl 1: S137; 
Medeiros-
Domingo et al. 
2009 
C11814A S3938R Missense Cytosol 87 Tester et al 2006 
G11836A G3946S Missense Cytosol 88 Priori et al. 2002 
- G3946A Missense Cytosol 88 Davis et al. Heart 
Rhythm 2006; 3: 
P4-62.; 
Medeiros-
Domingo et al. 
2009 
C11876T S3959L Missense Cytosol 88 Tester et al. Heart 
Rhythm 2006; 6 
Suppl 1:S137.; 
Medeiros-
Domingo et al. 
2009 
G11916T M3972I Missense Cytosol 89 Medeiros-
Domingo et al. 
2009 
G11917C D3973H Missense Cytosol 89 Medeiros-
Domingo et al. 
2009 
T11921A L3974Q Missense Cytosol 89 Medeiros-
Domingo et al. 
2009 
A11989G K3997E Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
- F4020L Missense Cytosol 90 Postma et al. 
2005 
A12226G E4076K Missense Cytosol 90 Postma et al. 
2005 
C12312G N4104K Missense Trans-Menbrane 90 Priori et al. 2001; 
Domain 
A12311T N4104I Missense Trans-Menbrane 
Domain 
90 Postma et al. 
2005 
- L4105F cSNP Trans-Menbrane 
Domain 
90 Hasdemir C et al. 
2008 
C12322A H4108N Missense Trans-Menbrane 
Domain 
90 Postma et al. 
2005 
- H4108Q Missense Trans-Menbrane 
Domain 
90 Postma et al. 
2005 
A12370G S4124G Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
- R4144C Missense Cytosol 90 Berge et al 2008; 
Medeiros-
Domingo et al. 
2009 
A12446G Y4149s Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
G12470A R4157Q Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
A12476G Q4159P Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
A12533G N4178S Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
G12559C E4187Q Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
C12601A Q4201R Missense Trans-Menbrane 
Domain 
90 Laitinen et 
al.2001 
C12845T A4282V cSNP Cytosol 90 Tester et al. 
Circulation 
2005; 11; 516. 
Medeiros-
Domingo et al. 
2009 
C12919T R4307C cSNP Cytosol 90 Callis et al. 
Heart Rhythm 
2009;6 Suppl 
1;S197.; 
Medeiros-
Domingo et al. 
2009 
G12944A G4315E Missense Cytosol 90 Medeiros-
Domingo et al. 
2009 
G13291A E4431K Missense Cytosol 91 Berge et al 2008; 
Medeiros-
Domingo et al. 
2009 
C13489T R4497C Missense Trans-Menbrane 
Domain 
93 Priori et al. 2001; 
Tester et al 2004 
G13512A M4504I Missense Trans-Menbrane 
Domain 
93 Bagattin et al 
2004 
A13528G A4510T Missense Trans-Menbrane 
Domain 
93 Laitinen et 
al.2001; Tester 
2005
(2)
 
- F4511L Missense Trans-Menbrane 
Domain 
93 Beckmann et al 
2008 
G13666A A4556T Missense Trans-Menbrane 
Domain 
94 Tester 2005(2) 
C13695A S4565R Missense Trans-Menbrane 
Domain 
94 Tester et al 
2007.; Medeiros-
Domingo et al. 
2009 
G13957T V4653F Missense Trans-Menbrane 
Domain 
97 Laitinen et 
al.2001 
G13819C A4607P Missense Trans-Menbrane 
Domain 
95 Bagattin et al 
2004 
G13831A E4611K Missense Trans-Menbrane 
Domain 
95 Berge et al 2008; 
Medeiros-
Domingo et al. 
2009 
- W4645R Missense Trans-Menbrane 
Domain 
96 Beery et al 2009; 
Medeiros-
Domingo et al. 
2009 
A13948G K4650E Missense Trans-Menbrane 
Domain 
96 Medeiros-
Domingo et al. 
2009 
13967-
13972DUP 
4657-
4658EYins 
EY 
Duplication Trans-Menbrane 
Domain 
97 Tester 2005(2) 
- G4662S Missense Trans-Menbrane 
Domain 
97 Postma et al. 
2005 
G14010C G4671R Missense Trans-Menbrane 
Domain 
97 Tester 2005(2) 
G14011C G4671R Missense Trans-Menbrane 
Domain 
97 Choi et al 2004 
14205-14208 
Del 
N4736 Del Deletion Trans-Menbrane 
Domain 
99 Medeiros-
Domingo et al. 
2009 
A14285C H4762P Missense Trans-Menbrane 
Domain 
99 Postma et al. 
2005 
G14311A V4771I Missense Trans-Menbrane 
Domain 
100 Priori et al. 2002 
G14369A R4790Q Missense Trans-Menbrane 
Domain 
100 Medeiros-
Domingo et al. 
2009 
A14414G K4805R Missense Trans-Menbrane 
Domain 
100 Medeiros-
Domingo et al. 
2009 
G14465A R4822H Missense Trans-Menbrane 
Domain 
101 Medeiros-
Domingo et al. 
2009 
- G4671V Missense Trans-Menbrane 
Domain 
97 Haugaa et al 
2010  
A14542G I4848V Missense Trans-Menbrane 
Domain 
101 Choi et al 2004; 
Tester 2005(2) 
T14552G F4851C Missense Trans-Menbrane 
Domain 
101 Aizawa et a 2006 
C14579G A4860G Missense Trans-Menbrane 
Domain 
101 Priori et al. 2002 
T14601G I4867M Missense C-terminal 102 Priori et al. 2002 
T14639C V4880A Missense C-terminal 102 Bagattin et al 
2004 
A14683G N4895D Missense C-terminal 103 Priori et al. 2002 
C14705T P4902L Missense C-terminal 103 Laitinen et al. 
2003 
- P4902S Missense C-terminal 103 Postma et al. 
2005 
G14806A G4936R Missense C-terminal 104 Medeiros-
Domingo et al. 
2009; Johnson et 
al 2010  
G14848A E4950K Missense C-terminal 105 Priori et al. 2002 
G14876A R4959Q Missense C-terminal 105 Laitinen et al. 
2003; Allouis et 
al 2005; Tester 
2005(2) 
 
Modified from  http://www.fsm.it Gene Connection from the Heart by Prof Silvia G. Priori 
and Dr Carlo Napolitano, with permission.  
cSNP = single nucleotide polymorphisms with a coding effect. 
 
 
 
Table 2- CASQ2 Mutations 
 
Modified from  http://www.fsm.it Gene Connection from the Heart by Prof Silvia G. Priori 
and Dr Carlo Napolitano, with permission. 
 
Nucleotide  
Change  
Amino Acid 
Change  
Mutation  
Type  
Protein  
Domain  
References  
62delA L23fs+14X Deletion/frameshift  Postma et al 2002 
97 C>T R33X Nonsense  Postma et al 2002 
98 G>A R33Q Missense   Terentyev et al 2006 
IVS4+1 
g>a 
-- Nonsense  Postma et al 2002 
164A>G Y55C Missense   deLa Fuente 2008  
339-354del G112+5X Deletion/frameshift Domain I Raffaele di Barletta et al 
2006 
500 T>A L167H
(3) Missense Domain II  Raffaele di Barletta et al 
2006 
529 G>C  E177Q Missense Domain II  Wong et al. 2009  
-  F189L Missense Domain II  Liu et al 2008  
618 A>C  K206N Missense Domain II  Kirchhhefer et al. 2010  
1038 G>A D307H
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